Category: 185815-59-2

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.185815-59-2,4-Isobutyldihydro-2H-pyran-2,6(3H)-dione,as a common compound, the synthetic route is as follows.

General procedure: To the 0.1 M toluene solution of anhydride (10 mmol), alkaloid (0.1 equiv), xanthene-9-carboxylic acid (0.2 equiv), and alcohol (1.5 equiv) were added. The reaction mixture was stirred until >90% conversion was reached (see Table 3) and the reaction was stopped by the addition of 5% HCl. The organic layer was washed once more with 5% HCl and evaporated. The oily residue was dissolved in 2% K2CO3 and washed successively with EtOAc. The aqueous solution was then carefully acidified with H3PO4 to pH 5.4 and extracted with toluene. The organic extracts were dried over Na2SO4 and evaporated in vacuo.

As the paragraph descriping shows that 185815-59-2 is playing an increasingly important role.

Reference£º
Article; Iv?i?, Trpimir; Novak, Jurica; Do?li?, Nada; Hamer?ak, Zdenko; Tetrahedron; vol. 68; 39; (2012); p. 8311 – 8317;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.185815-59-2,4-Isobutyldihydro-2H-pyran-2,6(3H)-dione,as a common compound, the synthetic route is as follows.

Cool the dark brown oil (D number) obtained in the previous step to room temperature.Dilute with 147 g of methyl tert-butyl ether;Add 114g concentrated ammonia water and 215ml water to the 1000ml reaction bottle to cool down;The above mixed droplets are added to the ammonia water under stirring at 25 C or lower.After the dropwise addition is completed, the reaction is continued for 35 minutes at 25 C or lower;After the reaction is completed, the layers are separated, and the organic layer is extracted under reduced pressure. The aqueous layer is slowly adjusted to pH = 1.5 with concentrated hydrochloric acid (about 119 g) under stirring, and a large amount of solid is precipitated. After the completion of the dropwise addition, the temperature is lowered to 0 to 10 C, filtered, and filtered. The cake was washed with 115 ml, and the crude product was dried under reduced pressure. The dried crude product was dissolved in ethyl acetate 615 ml at 70 C, then filtered, cooled and crystallized, cooled to 0 to 5 C, filtered, and the filter cake was washed with 115 ml of iced ethyl acetate, and then dried under reduced pressure.110.9 g of amide (trait: white solid, melting point 106-108 C),The yield was 59.3% (based on ethyl cyanoacetate).

The synthetic route of 185815-59-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Langfang Zekang Pharmaceutical Technology Co., Ltd.; Sun Yuqin; Yang Weimin; (5 pag.)CN109320430; (2019); A;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.185815-59-2,4-Isobutyldihydro-2H-pyran-2,6(3H)-dione,as a common compound, the synthetic route is as follows.

Example 10: Preparation of (3R)-5-methyl-3-(2-oxo-2(r(lR)-l-phenylethyl1amino>ethyl) hexanoic acid compound (24); [0084] A three-necked flask equipped with an addition funnel, thermometer pocket, drying tube and a mechanical stirrer, was charged with a mixture of cyclohexane and toluene EPO (100 ml) in a ratio of 1 to 1, (R)-(+)-phenylethylamine (35.58 g, 0.147mole) and 4-dimethylaminopyridine (0.18 g, 0.00147 mole). The mixture was cooled to a temperature of 0-5 C, followed by addition of a solution of 3-isobutyl glutaric anhydride (25 g, 0.147 mole) in mixture of cyclohexane and toluene (100 ml) in a ratio of 1 to 1, (25 ml), over a period of 15-20 minutes, and stirring for additional 1.5-2 hours, at a temperature of 0-5C. The mixture was then extracted with 2.5-3 percent aqueous solution of NaOH solution (500 ml), and the aqueous phase was washed with toluene (1 x 50 ml). The pH of the aqueous phase was adjusted to 2-2.5 by adding a 1-12N solution of hydrochloric acid. The aqueous phase was further extracted with ethyl acetate (1 x 150 ml and 1 x 50 ml), followed by drying the combined ethyl acetates extracts over anhydrous sodium sulfate, and stripping off the solvents, to obtain a residue. The residue was crystallized from ethyl acetate and toluene mixture to get 28.7 g (67 percent yield) of a white solid of (3R)-5-methyl-3-(2-oxo-2-{[(lR)- 1-phenylethyl] amino }ethyl)hexanoic acid with an optical purity of 99.34 percent, as measured by chiral HPLC.

185815-59-2 4-Isobutyldihydro-2H-pyran-2,6(3H)-dione 11480690, aTetrahydropyrans compound, is more and more widely used in various.

Reference£º
Patent; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.; WO2007/35789; (2007); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics